V
42.72
2.52 (6.27%)
| Previous Close | 40.20 |
| Open | 40.17 |
| Volume | 632,418 |
| Avg. Volume (3M) | 546,770 |
| Market Cap | 2,342,239,488 |
| Price / Book | 6.83 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.19 |
| Total Debt/Equity (MRQ) | 16.11% |
| Current Ratio (MRQ) | 21.43 |
| Operating Cash Flow (TTM) | -106.73 M |
| Levered Free Cash Flow (TTM) | -74.73 M |
| Return on Assets (TTM) | -24.74% |
| Return on Equity (TTM) | -46.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vera Therapeutics, Inc. | Bearish | Bullish |
Stockmoo Score
0.3
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.30 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.85% |
| % Held by Institutions | 108.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sofinnova Investments, Inc. | 30 Jun 2024 | 2,793,987 |
| Eversept Partners, Lp | 30 Jun 2024 | 2,043,214 |
| Holocene Advisors, Lp | 30 Jun 2024 | 1,796,077 |
| First Light Asset Management, Llc | 30 Jun 2024 | 1,005,723 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 107.00 (Cantor Fitzgerald, 150.47%) | Buy |
| Median | 72.00 (68.54%) | |
| Low | 60.00 (Scotiabank, 40.45%) | Buy |
| Average | 79.67 (86.49%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 39.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 16 Oct 2024 | 60.00 (40.45%) | Buy | 39.99 |
| Cantor Fitzgerald | 03 Oct 2024 | 107.00 (150.47%) | Buy | 40.49 |
| 01 Oct 2024 | 107.00 (150.47%) | Buy | 42.83 | |
| JP Morgan | 03 Sep 2024 | 72.00 (68.54%) | Buy | 38.36 |
| 13 Aug 2024 | 62.00 (45.13%) | Buy | 37.95 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FORDYCE MARSHALL | - | 38.93 | -15,625 | -608,281 |
| Aggregate Net Quantity | -15,625 | |||
| Aggregate Net Value ($) | -608,281 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 38.93 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FORDYCE MARSHALL | Officer | 09 Oct 2024 | Automatic sell (-) | 15,625 | 38.93 | 608,281 |
| FORDYCE MARSHALL | Officer | 09 Oct 2024 | Option execute | 15,625 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |